635712-89-9 Usage
General Description
4,5,6,7-Tetrahydro-7,7-dimethyl-1H-pyrazolo[4,3-c]pyridine hydrochloride is a chemical compound with a complex molecular structure. It is classified under the category of pyridines, which are aromatic compounds containing a ring with two nitrogen atoms and five carbon atoms, and are often used as building blocks in the production of drugs, pesticides and other useful compounds. The tetrahydro- prefix in its name signifies the presence of four hydrogen atoms, while dimethyl indicates two methyl groups consisting of one carbon atom and three hydrogen atoms each. These, along with the pyrazolo and pyridine rings indicate a highly structured and potentially reactive molecule. The hydrochloride suffix also denotes the presence of a hydrochloride salt, which can improve the solubility and absorption of the compound. However, specific uses and properties of this individual compound may vary depending on its preparation and potential modifications.
Check Digit Verification of cas no
The CAS Registry Mumber 635712-89-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 6,3,5,7,1 and 2 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 635712-89:
(8*6)+(7*3)+(6*5)+(5*7)+(4*1)+(3*2)+(2*8)+(1*9)=169
169 % 10 = 9
So 635712-89-9 is a valid CAS Registry Number.
InChI:InChI=1/C8H13N3.ClH/c1-8(2)5-9-3-6-4-10-11-7(6)8;/h4,9H,3,5H2,1-2H3,(H,10,11);1H
635712-89-9Relevant articles and documents
Calcitonin gene related peptide receptor antagonists
-
, (2008/06/13)
The present invention relates to compounds of Formula (I) as antagonists of calcitonin gene-related peptide receptors (“CGRP-receptor”), pharmaceutical compositions comprising them, methods for identifying them, methods of treatment using them and their use in therapy for treatment of neurogenic vasodilation, neurogenic inflammation, migraine and other headaches, thermal injury, circulatory shock, flushing associated with menopause, airway inflammatory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), and other conditions the treatment of which can be effected by the antagonism of CGRP-receptors.
